U.S. Markets close in 5 hrs 11 mins
  • S&P 500

    -3.99 (-0.09%)
  • Dow 30

    -56.71 (-0.16%)
  • Nasdaq

    -12.56 (-0.08%)
  • Russell 2000

    +17.55 (+0.79%)
  • Crude Oil

    -0.31 (-0.43%)
  • Gold

    -1.90 (-0.11%)
  • Silver

    +0.04 (+0.15%)

    +0.0047 (+0.4018%)
  • 10-Yr Bond

    -0.0200 (-1.56%)
  • Vix

    +1.41 (+8.20%)

    +0.0070 (+0.5073%)

    -0.3270 (-0.2959%)

    +4,363.72 (+12.86%)
  • CMC Crypto 200

    +0.54 (+0.06%)
  • FTSE 100

    -9.21 (-0.13%)
  • Nikkei 225

    +285.29 (+1.04%)

Ionis (IONS) Crashes as Roche-Partnered Huntington's Drug Fails

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Ionis Pharmaceuticals IONS plunged 20% on Monday after its partner Roche RHHBY announced its decision to stop dosing in a phase III study of tominersen in Huntington’s disease (HD), a rare neurodegenerative disease. The decision was taken on the recommendation of an Independent Data Monitoring Committee (iDMC) which was based on a pre-planned review of the data from the study (GENERATION HD1) by the committee.

No new safety signals were identified in the review for the candidate. However, iDMC’s recommendation was based on potential benefit/risk profile for study participants.

Meanwhile, Roche said that dosing will also be paused in the open-label extension study (GEN-EXTEND) of tominersen. It will analyze the results of the phase III study. Meanwhile, the phase I PK/PD study (GEN-PEAK) of tominersen and the observational Roche HD Natural History Study will continue

This year so far, the company’s shares have declined 1.6% against an increase of 2.3% for the industry.

Tominersen was a key late-stage candidate in Ionis partnered pipeline. Ionis has six pivotal phase III studies ongoing for five medicines (internal as well as partnered), which include other than tominersen, tofersen for SOD1- Amyotrophic lateral sclerosis (ALS), pelacarsen for cardiovascular disease due to elevated Lp(a) levels; IONIS-APOCIII-LRx for familial chylomicronemia syndrome, or FCS and IONIS-TTR-LRx for TTR amyloidosis. While tofersen is being developed in partnership with Biogen BIIB, pelacarsen is being developed with Novartis NVS. Ionis is developing IONIS-APOCIII-LRx for FCS and IONIS-TTR-LRx for TTR on its own.

Ionis currently carries a Zacks Rank #4(Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Roche Holding AG (RHHBY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research